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Abstract
GNAS/Gnas encodes Gsa that is mainly biallelically expressed but shows imprinted expression in some tissues. In Albright
Hereditary Osteodystrophy (AHO) heterozygous loss of function mutations of GNAS can result in ectopic ossification that
tends to be superficial and attributable to haploinsufficiency of biallelically expressed Gsa. Oed-Sml is a point missense
mutation in exon 6 of the orthologous mouse locus Gnas. We report here both the late onset ossification and occurrence of
benign cutaneous fibroepithelial polyps in Oed-Sml. These phenotypes are seen on both maternal and paternal inheritance
of the mutant allele and are therefore due to an effect on biallelically expressed Gsa. The ossification is confined to
subcutaneous tissues and so resembles the ossification observed with AHO. Our mouse model is the first with both
subcutaneous ossification and fibroepithelial polyps related to Gsa deficiency. It is also the first mouse model described with
a clinically relevant phenotype associated with a point mutation in Gsa and may be useful in investigations of the
mechanisms of heterotopic bone formation. Together with earlier results, our findings indicate that Gsa signalling pathways
play a vital role in repressing ectopic bone formation.
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Introduction
GNAS encodes Gsa, the alpha stimulatory subunit of the widely
expressed heterotrimeric protein, Gs, that is required for hormone
stimulated cAMP production [1]. Heterozygous loss of function
mutations in GNAS can result in genetic disorders in which ectopic
bone formation occurs [2,3]. These include progressive osseous
heteroplasia (POH), osteoma cutis (OC) and Albright Hereditary
Osteodystrophy, (AHO) [4,5,6]. In POH ectopic bone formation
in the dermis and subcutaneous fat progresses to deep connective
tissue and skeletal muscle resulting in joint deformities, with
mounting evidence indicating that this condition occurs predom-
inantly on paternal inheritance of inactivating GNAS mutations
[4,7]. In both POH and AHO the majority of ossification is
intramembranous rather than endochondral [8] but the ossifica-
tion that occurs with AHO and OC tends to be superficial. Also
additional features are not usually found with POH and OC.
However, AHO is also characterised by short stature, round face,
brachymetacarpia, dental abnormalities and neurobehavioural
problems [9]. These features, and also the subcutaneous ossifica-
tion, are attributable to haploinsufficiency of Gsa in a number of
tissues, and are found both on maternal and paternal transmission
of the mutant allele. Thus, some patients develop AHO and others
POH on paternal inheritance of inactivating GNAS mutations
although the reasons for this are not clear.
Maternal inheritance of an inactivating GNAS mutation results
in AHO with additional features of obesity and resistance to a
variety of hormones, including parathyroid hormone (PTH)
[10,11]. These additional phenotypes can be explained in terms
of the tissue specific imprinted expression of Gsa, which is
predominantly expressed from the maternal allele in specific
hormone target tissues. AHO combined with hormone resistance
is called PHP1a, pseudohypoparathyroidism type 1a, whereas
AHO that occurs on paternal inheritance of an inactivating GNAS
mutation without hormone resistance or severe obesity is called
PPHP, pseudopseudohypoparathyroidism [11]. It is noteworthy
that some patients develop POH, rather than PPHP, on paternal
inheritance of an inactivating mutation in GNAS. Although AHO
is generally associated with superficial ossification, subsets of
patients have been identified with progressive ossification and
PHP1a [4,7] or PPHP. Multiple inactivating mutations have been
described in humans that are associated with AHO [12,13,14] and
POH [7,15,16]; all result in the reduction of the Gsa protein,
resulting in loss of GDP and GTP binding. There appears to be no
genotype/phenotype correlation, and the same mutation can
present with different severity and distribution of lesions both
within an affected family and between different families [4]. GNAS
is a critical negative regulator of osteogenic commitment in non
osseous connective tissue [17]. It is thought that inactivation of the
Gsa protein results in cellular proliferation and differentiation and
activation of osteoblasts. However the exact signalling pathways
remain unknown.
The orthologous mouse locus Gnas is also imprinted and, as in
humans, Gsa shows tissue specific imprinted expression. Although
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51835
Gsa is biallelically expressed in most tissues in the mouse it is
mainly expressed from the maternal allele in renal proximal
tubules, newborn brown adipose tissue, pituitary and the
hypothalamus [18,19,20]. Furthermore the GNAS/Gnas loci are
similarly organized in both species with multiple alternatively
spliced protein coding transcripts arising from three different
promoter regions and first exons that splice onto exon 2 of Gnas
(Figure 1) [21,22]. The promoter furthest downstream generates
transcripts encoding Gsa. A promoter region upstream generates
transcripts for an isoform of Gsa called XLas which differs from
Gsa in that the first 47 amino acids are replaced by a large acidic
N-terminal domain. XLas shares many properties with Gsa,
including activation of adenylyl cyclase, thereby promoting cAMP
production [23]. XLas is paternal-specific and is only expressed in
a few tissues, mainly neuroendocrine tissues [24,25]. Neural-
specific isoforms of Gsa (GsaN1) and XLas (XLN1) that arise from
transcripts terminating in a neural exon located between exons 3
and 4 are known [26,27]. The promoter furthest upstream
generates transcripts for a chromogranin-like protein NESP55,
that is exclusively maternally expressed. The open reading frame
(ORF) for NESP55 is confined to its second exon, and is thus
distinct from the ORF for Gsa, and NESP55 deficient mice
develop normally [28].
Mutations designed to result in loss of function of Gsa, but leave
other proteins in the cluster unaffected have been generated by
targeted deletion of Gnas exon 1 [29,30]. Maternal inheritance
resulted in obesity [29,30] and resistance to PTH and TSH [30]
whereas paternal inheritance lead to a minimal increase in
adiposity [29] and normal hormone responsiveness [30], mimick-
ing the imprinting effects seen in PHP1A and PPHP. On both
maternal and paternal inheritance shorter body length was found
[30], resembling the observation of short stature in AHO,
attributable to loss of biallelic expression of Gsa.
The oedematous-small, Oed-Sml, mutation, derived from a
specific locus mutation experiment investigating the effects of
ethylnitrosourea on spermatogonial stem cells [31] is a missense
mutation in exon 6 of Gnas resulting in a V159E substitution [32].
When maternally inherited it causes the Oed phenotype, charac-
terized by extremely severe oedema at birth whereas paternal
inheritance gives rise to the Sml phenotype of postnatal growth
retardation [31]. In adult Oed mice the mutation also results in
resistance to PTH, hypocalcemia, hyperphosphatemia [19] and
obesity [33]; findings consistent with loss of function of Gsa. Thus
Oed constitutes a mouse model of PHP1a. On paternal transmis-
sion the Oed-Sml mutation will affect Gsa, but only in tissues in
which it is normally biallelically expressed. Paternal transmission
will additionally affect XLas. The neural forms GsaN1 and XLN1
will be unaffected. The dual effects on Gsa and XLas are probably
reflected in the short and lean phenotype found in adult Sml mice
[33].
We here report the finding of dermal ectopic ossification in both
Oed and Sml mice in adults up to 15 months of age. This phenotype
is similar on both maternal and paternal inheritance and is thus
attributable to haploinsufficiency of an effect on biallelically
expressed Gsa. The ossification is confined to subcutaneous tissues
and does not affect deeper tissue and so resembles the
subcutaneous ossification observed with AHO. Thus the Oed-Sml
mice provide a model of heterotopic ossification associated with
loss of function mutations in GNAS, and may be useful in
investigations of the mechanisms of heterotopic bone formation.
Results
Fibromatous skin masses in Sml and Oed mice
The first observed skin abnormalities in Sml and Oed mice were
pedunculated or sessile hairless skin masses commonly located on
the feet or tail (Figure 2A, 2C); there was only a single instance of a
mass occurring elsewhere and this was on the perineum.
Microscopically these skin masses were covered by sparsely haired
epidermis that could be focally ulcerated (Figure 2D, 2E).
Figure 1. Protein coding transcript map of the mouse Gnas cluster (modified from ref [66]). Features of the maternal and paternal alleles
are shown above and below the line. Arrows show direction of transcription. Transcripts arising from the first exons of protein coding transcripts,
Nesp, Gnasxl, and Gnas splice onto exon 2 of Gnas. For Gnas the unbroken arrow shows predominant maternal expression and the dotted line
indicates limited paternal expression. The asterisk indicates the Oed-Sml mutation in exon 6.
doi:10.1371/journal.pone.0051835.g001
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Underlying tissue consisted of a fibromatous proliferation of
uniform spindle cells and entrapped follicles and adnexae
(Figure 2E) reminiscent of a benign fibroma of human skin [34].
Skin masses with intralesional radiographic opacities (Figure 2B)
contained foci of bone that we interpret as osseous heteroplasia
(Figure 2F).
These skin masses were present from 6.5 months of age
onwards. During life, in Smlmice,10 months of age the incidence
was 17% (6/35) but no skin masses were seen in 15 +/+ sibling
controls. In Sml mice .12 months of age the incidence rose to
74% (39/53), significantly different from both the complete lack of
skin masses in 19 male +/+ sibling controls .12 months,
(P,0.0001 Fisher’s exact test) and in Sml mice ,10 months of
age (P,0.0001Fisher’s exact test). In Oed mice ,10 months of age
the incidence was 25% (5/20) significantly different (P,0.05) from
the absence of skin masses in 20 +/+ sibling controls. In Oed mice
.12 months of age the incidence was 52% (11/21), significantly
different from the complete absence of skin masses in 13 +/+
sibling controls (P,0.01) but not significantly different from the
incidence at ,10 months. The incidences of skin masses were not
significantly different in Sml and Oed at ,10 months or .12
months of age.
Widespread radiographic lesions in the skin
To explore whether osseous heteroplasia was confined to the
skin masses we took whole body x-rays and found radio-opacities
were more generalized. To determine whether radio-opacities
were superficial (in the dermis or subcutaneous fat) or deep (in
connective tissue and muscle) whole body radiographs were
obtained before skin dissection in a subset of 40 Sml and Oed mice
aged 12 and 15-months (18 Oed males, 15 Sml males and 7 Sml
females). In all cases there were no detectable adhesions between
the skin and underlying trunk and limb muscles and the skin
dissected cleanly. Furthermore the radio-opacities were accounted
for in the dissected skin (Figure 3A) and not in trunk or limb
musculature. In 6 and 9 month Sml and Oed male mice, the radio-
opacity number (range 0–48) and cumulative area (range 0–
18 mm2) overlapped and did not significantly differ (P.0.05) from
their respective +/+ controls (Figure 3B and 3C). A single outlier
+/+ male with wounded skin gave the high value of 48 lesions with
a cumulative area of 18 mm2. At 12 and 15 months radiographic
changes had risen significantly (P,0.001) in Sml males (range 0–37
and 0–36 mm2) over +/+ controls (range 0–8 and 0–0.3 mm2). In
Oed males radiographic changes (range 0–49 and 0–77 mm2) were
significantly higher (P,0.01) than +/+ controls (zero for both
parameters) (Figure 3B and 3C).
In Sml and Oed female mice, the number (range 0–3) and
cumulative area (range 0–0.4 mm2) of radio-opacities were low
and not significantly different (P.0.05) from their respective +/+
controls at 6 and 9 months. However, by 12 and 15 months, both
radiographic changes had risen in Sml females (range 0–11 and 0–
16 mm2) significantly (P,0.05, and P,0.01 respectively) above +/
+ control levels (range 0–2 and 0–8 mm2) (Figure 3D and 3E).
Radiographic lesions in the skin correspond to foci of
osseous heteroplasia
Skin histology revealed that areas with radio-opacities
(Figure 3A) corresponded to foci of subcutaneous and dermal
osseous heteroplasia characterized by irregular bone lamellae with
osteoclasts within lacunae (Figure 3F). Some of the bone foci had
large lacunae lined with osteoblasts and accumulations of
hematopoietic tissue (Figure 3G). When skin samples from Sml
and Oed mice with radio-opacities were systematically examined
for underlying histological changes, 60% (6/10) and 91% (32/35)
were confirmed to have foci of dermal or subcutaneous ossification
in 6 & 9 month-old and 12 & 15 month-old cohorts respectively
(Table 1). In contrast, mineralization of dermal or subcutaneous
connective tissue characterized by basophilic extracellular collag-
enous stroma was a less common finding than bone in Sml and Oed
12 & 15 month-old mice (Table 1). Dermal or subcutaneous bone
was found in significantly fewer 12 & 15 month +/+ mice
compared with Sml and Oed mice (11% [3/27] versus 92% [35/
38]; P,0.0001) (Table 1). In some +/+ mice, bone was associated
with injury to overlying skin whereas the majority of instances of
dermal bone in Sml and Oed mice occurred beneath intact
uninjured epithelium (Figure 3F, 3G). Sixteen Sml and Oed mice
from 6 & 9 and 12 & 15 month old cohorts that had confirmed
dermal or subcutaneous bone underwent a systematic histological
Figure 2. Fibromatous skin masses in Sml and Oedmice. (A) An ulcerated pedunculated hairless mass on the front paw (arrow) of 7-month-old
Oedmale mouse. (B) X-ray of this lesion shows radio-opacities (arrow). (C) A hairless nodule on the tail (arrow) of a 12-month-old Oedmale mouse. (D,
E and F) A pedunculated mass in a 8-month-old Oed male mouse. (D) This mass has a narrow pedicel (arrow p) and is focally ulcerated (arrow u). (E)
Intact hyperkeratotic epithelium (arrow e) bordering a mass of fibromatous connective tissue (arrow f) with an entrapped follicle (arrow ef) and
associated sebaceous gland. (F) Focal areas of osseous heteroplasia (arrow o) within the fibromatous mass (arrow f). Scale bars: A,B,C = 0.5 mm;
D= 1 mm; E = 100 mm; F = 50 mm.
doi:10.1371/journal.pone.0051835.g002
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Figure 3. Skin radio-opacities increase with age in Sml and Oedmice and correspond to foci of osseous heteroplasia. (A) X-ray image
of radio-opacities in the skin of a 12-month-old Sml male imaged on a 161 cm grid. (B) The number and (C) cumulative area of skin radio-opacities in
Sml and Oed male mice at 6 & 9 months of age are not significantly different from +/+ controls, however they are significantly increased in the 12 &
15-month-old cohorts compared to +/+ mice. (D) The number and (E) cumulative area of skin radio-opacities in Sml and Oed females at 6 & 9 months
of age are not significantly different from +/+ controls, however they are significantly increased in the 12 & 15-month-old Sml compared to +/+
controls. In the box and whisker plots each box represents the median with 25 and 75% inter-quartile ranges, with whiskers representing the data
range (minimum and maximum). The group size n is indicated alongside each histogram bar, whereas the circled numbers are the off-scale maximum
values. ns = not significant P.0.05, * P,0.05, **P,0.01, ***P,0.001. Kruskall Wallis non-parametric one-way ANOVA tests were performed with
Dunn’s multiple comparison tests for post hoc testing. { A single male +/+ control with high levels of radio-opacities was an outlier that had a
wounded skin. (F). Radio-opacities correspond to foci of osseous heteroplasia (arrow o) with osteoclasts (arrow oc) beneath intact skin. (G) Focus of
hematopoietic tissue (arrow h) within an area of osseous heteroplasia, inset is enlarged view (arrow h), the bone surface has an osteoblast layer
(arrow ob). Scale bars: F = 100 mm; G= 200 mm.
doi:10.1371/journal.pone.0051835.g003
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examination of internal organs and revealed unremarkable low
background incidence of bony change and mineralization. One
mouse had small foci of bone in the lung, 4 had minimal focal
mineralization in various organs including the kidney, Harderian
gland, stomach, intestines and male accessory reproductive gland.
The finding of late onset osseous heteroplasia on both paternal and
maternal inheritance of the Oed-Sml mutation suggests that these
lesions are due to haploinsufficiency of Gsa.
Plasma biochemistry
In young adult Oed mice the Gnas mutation results in resistance
to PTH, hypocalcemia and hyperphosphatemia [19]. We there-
fore examined whether similar changes occurred in older Oed mice
and in Sml mice, since they could conceivably play a role in
osseous heteroplasia.
In Oed males PTH was highly elevated at 6 & 9 months
(266624 pmol/L versus 1764 pmol/L; P,0.0001) and at 12 &
15 months (249636 pmol/L versus 2265 pmol/L; P,0.0001)
compared with +/+ controls. The moderate elevation in PTH in
Sml males did not achieve statistical significance at 6 & 9 months
(88629 pmol/L versus 1865 pmol/L; P=0.054) but at 12 & 15
months was significant (71613 pmol/L versus 1965 pmol/L;
P,0.002) (Figure 4A).
Plasma calcium corrected for albumin in Oed males was
significantly lower than their respective +/+ controls at 6 & 9
months (2.160.08 mmol/L versus 2.360.02 mmol/L, P=0.029),
but not at 12 & 15 months. Calcium in Sml males was not
significantly lower than in their respective +/+ controls at 6 & 9
months but was lower than controls at 12 & 15 months
(2.160.09 mmol/L versus 2.460.04 mmol/L, P=0.0021).
Plasma phosphate levels in Oed males were significantly higher
compared with their respective +/+ controls at 6 & 9 months
(2.760.18 mmol/L versus 1.960.23 mmol/L, P=0.014), but not
at 12 & 15 months. Plasma phosphate in Sml males was not
significantly different from +/+ controls at 6 & 9 months and at 12
& 15 months was actually lower than +/+ controls
(2.060.12 mmol/L versus 2.660.14 mmol/L, P=0.0021).
Discussion
In this animal model we have identified both radiological and
pathological evidence of heterotopic ossification or osteoma cutis
(the formation of mature bone in soft tissues). In this study we have
analysed two cohorts of 6 & 9 month (n=52) and 12 & 15 month
(n=102) Oed/Sml mice and their +/+ controls. In summary we
identified: (a) a statistically significant increase in soft tissue lesions
(histologically confirmed as fibroepithelial polyps) in aged Sml and
Oed mice; (b) a statistically significant increase in both the number
and cumulative area of radio-opacities in aged Oed and Sml male
and female mice; and (c) highly elevated PTH levels in both
younger and older Oed mice and moderately elevated PTH levels
in older Sml mice.
The first observed skin phenotype, benign cutaneous fibroep-
ithelial polyps, is similar on both maternal and paternal
inheritance of the Oed-Sml mutation and are thus attributable to
haploinsufficiency of biallelically expressed Gsa. These fibromas
have some resemblance to the skin angiofibromas described by
Sakamoto et al. [35] in their exon 2 Gnas deletion model.
It is interesting to note that the fibromas described in the latter
model were stated to arise in a similar distribution to ours on the
ear, paws and tail, occurred with a similar age and sex distribution,
and were associated with calcification. Sakamoto et al. [35] state
that pre-existing trauma may be a predisposing factor, which may
be a similar cause in our model considering the similarities in
lesional distribution, the only difference being we did not find
fibromas on the ears in our model despite inadvertent injury to the
ear caused by notching for identification/genotyping.
In the Sakamoto et al. paper [35] all lesions were associated
with calcification only, while in our study, we identified three
lesions that were associated with ossification. However we did not
serially section all lesions to confirm the presence or absence of
microscopic ossification in others. It is unclear whether these
lesions represent a subset of dermal ossification lesions that became
pedunculated or were associated with additional fibrous prolifer-
ation, or whether they represent a separate entity with additional
etiology.
Although we identified a statistically significant increase in soft
tissue polypoid lesions in this model, the clinical significance is
unclear. In our review of the clinical literature of AHO and
PHP1A patients there is no mention of soft tissue lesions as
described by us or by Sakamoto et al. [35].
The second phenotype, namely subcutaneous ossification and
calcification, was observed both radiologically and confirmed by
histological examination. Previous mouse models of inactivating
Gnas mutations generated via a variety of mechanisms have also
shown evidence of superficial heterotopic ossification [17,36,37]
with similar histological features to those found in our model. In a
conditional renin induced exon 1 Gnas deletion model, skin
mineralisation plus additional skeletal deformities were observed in
both male and female mice with local deletion of Gnas in both the
kidney and extrarenal tissues including skin [36]. In a separate
targeted exon 1 deletion model generated by Huso et al. [37],
heterozygous male and female mice developed non-progressive
subcutaneous ossifications related to sites of trauma with ageing. In
our study, we also identified late onset heterotopic ossification
confined to subcutaneous tissues on both maternal and paternal
inheritance of the Oed-Sml mutation. Overall, heterotopic ossifica-
tion is similar in both Oed and Sml indicating that the difference in
genetic background has not had a significant effect on the
phenotype. The Oed-Sml mutation will affect biallelically expressed
Gsa in both Oed and Sml, imprinted Gsa in Oed, and imprinted
XLas in Sml. The similarity in the ossification phenotype in both
Table 1. Histological analysis of skin x-ray radio-opacities in
Oed and Sml mice.
skin x-ray histology
osseous
radio-opacity heteroplasia mineralization
6 & 9
month
+/+ (n= 22) 3 0 0
Sml (n=10) 5* 2ns 1
Oed (n= 13) 5ns 4* 1
12 & 15
month
+/+ (n= 27) 3 3 1
Sml (n=19) 16*** 16*** 1ns
Oed (n= 19) 19*** 16*** 2ns
262 Fisher Exact tests were used to compare proportions of Sml or Oed with +/
+ control mice bearing each lesion. ns = not significant P.0.05,
*P,0.05,
***P,0.001.
doi:10.1371/journal.pone.0051835.t001
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Oed and Sml indicates that it is attributable to partial loss of Gsa in
tissues in which Gnas is biallelically expressed, not to imprinted Gsa
or XLas. Thus the ENU mutation resulting in Oed and Sml gives
rise to a bone phenotype more in keeping with that generally
associated with AHO (both PHP1A and PHPP) rather than POH,
in that it is confined to superficial tissues and is attributable to
haploinsufficiency of biallelically expressed Gsa.
Patients with PHP1A develop PTH resistance and associated
hypocalcemia and hyperphosphatemia, features attributable to
imprinted expression of GNAS [3]. Oed mice with a maternally
derived mutant Oed-Sml allele were known to have highly elevated
PTH levels at 10 weeks of age [19], and have now been shown to
have highly elevated PTH levels up to 15 months of age. Gnas
shows imprinted expression in proximal renal tubules, the primary
site of PTH action in the kidney [18,19,30,38,39]. However, in
imprinted tissues Gnas appears to be predominantly but not
exclusively expressed from the maternally derived allele with about
70–80% expression from the maternal allele and 20–30% from the
paternal allele [18,38,40]. It had also been shown previously that
Oed mice that additionally carried a mutation leading to loss of
imprinting of Gnas so resulting in biallelic expression of Gnas did
not have, as expected, a wild type concentration of PTH but one
that was intermediate between wild type and Oed [19]. To account
for this intermediate level it was proposed that whereas the now
functional paternal allele enabled normal PTH signaling the
mutant maternal allele did not. Thus the Oed-Sml allele probably
generates a mutant Gsa polypeptide that can associate with Gsb
and Gsc polypeptides to form a heterotrimeric Gs protein but one
that that is non functional, and so PTH signaling activity is
restricted resulting in a partial normal response to PTH [19].
A similar argument for a partial normal response to PTH can be
put forward to account for the moderate elevation in PTH
concentration in Sml mice in the present study. In these mice it is
expected that 70–80% of the Gnas expression in proximal renal
tubules will be from the wild type functional maternal allele and
20–30% from the mutant nonfunctional paternal allele. The wild
type maternal allele will enable normal PTH signaling but the
mutant paternal allele will not, so curtailing overall signaling
activity through Gsa and accounting for some elevation in the
PTH level but to a much lesser extent than in Oed mice.
Although hypocalcemia and hyperphosphatemia were found to
be associated with the highly elevated PTH levels at 10 weeks of
age in Oed mice [19] and now at 6 & 9 months in this study,
hypocalcemia and hyperphosphatemia did not occur at 12 & 15
months in Oedmice and the reason(s) for this are unclear. Although
hypocalcemia was associated with the moderate elevation in PTH
in Smlmice at 12 and 15 months, hyperphosphatemia was not seen
and indeed the mice were hypophosphatemic relative to their
respective controls, and the reason(s) for this is are not clear.
It should be noted that the average plasma calcium (2.1–
2.4 mmol/L) and phosphate (1.9–2.7 mmol/L) levels for all
cohorts in this study are close to MRC Harwell baselines found
in 18 week old mice in other inbred mouse strains (C57BL/6,
BALB/c, C3H and 129) (see data deposited in http://
europhenome.org). Although Oed and Sml mice are on a different
genetic background to these inbred strains and are older, the
observation that plasma calcium and phosphate levels found in Oed
Figure 4. Plasma biochemistry phenotypes of male Sml and Oedmice. (A) Plasma PTH was significantly elevated in Oed mice at 6 & 9 and 12
& 15 months of age compared to +/+ controls. The modest elevation in Sml PTH levels at 6 & 9 months failed to reach significance (P= 0.053) but PTH
was significantly elevated at 12 & 15 months compared with respective +/+ controls. Plasma calcium corrected for albumin levels (B) in Oed mice was
lower than their respective +/+ controls at 6 & 9 months but not at 12 & 15 months. Calcium in Sml males was not lower than in their respective +/+
controls at 6 & 9 months but was lower than controls at 12 & 15 months. Plasma phosphate levels (C) in Oed mice were higher compared with their
respective +/+ controls at 6 & 9 months but not at 12 & 15 months. Plasma phosphate in Smlmales was not significantly different from +/+ controls at
6 & 9 months and at 12 & 15 months was lower than +/+ controls. The group size n is indicated alongside each histogram bar, the error bar is6 s.e.m;
ns = not significant P.0.05, *P,0.05, **P,0.01, ***P,0.001. 2-tailed t-tests with unequal group variance were performed on the PTH data.
doi:10.1371/journal.pone.0051835.g004
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and Sml mice are within normal limits for other strains of mice
raises the question whether the relative degree of hypocalcaemia
and hyperphosphatemia is either pathological or contributory to
the development of osseous heteroplasia. The absence of any
significant degree of dermal mineralization in Oed and Sml mice
suggests that the changes in are not in themselves pathological.
Taken together, tissue calcification does not occur as a direct
consequence of PTH resistance nor does tissue calcification appear
to be critical to the development of osseous heteroplasia in Oed,
and Sml mice.
We have reviewed the clinical literature of patients with AHO
or PHP1a who have had additional mutational analysis (Table S1).
Of a total 120 patients with either syndrome reported in the
literature, 61 were stated to have superficial subcutaneous
calcifications which were either multiple or single plaque like
lesions, located frequently on the abdomen, back, limbs and digits
(Table S1). Some calcifications were reported to be associated with
ossification; in other patients osteomas were identified as well as
subcutaneous calcification. Rarely intracerebral calcification was
reported but there was no reference to either progressive or deep
calcification of other organs in these patients. Of significance, our
review of 120 patients reported in the literature with either AHO
or PHP1a and mutational analysis revealed that there was no
report of subcutaneous fibromas or fibroepithelial polyps in any of
the patients investigated. In one patient there is reference to a
calcifying aponeurotic fibroma with central osteoid formation
which may have in fact been a polypoid osteoma [41]. It appears
therefore that there is no correlation between fibroma observed in
our model and that of Sakamoto et al. [35] and the human clinical
syndromes AHO and PHP1a [4,7,12,41–63] (Table S1).
A wide range of genetic mutations were identified in these
patients ranging from insertion and deletions of base pairs leading
to frameshift mutations, premature termination and truncated
proteins to missense mutations in which a particular amino acid
was substituted. There was no clear genotype-phenotype correla-
tion, though there appeared to be two mutation hotspots in exon 7
and exon 10. Although there are no reported patients with the
exact missense mutation created in the Oed/Sml mouse (V159E),
there are reports of two patients with other missense mutations in
exon 6 (Table S1). One mutation is in codon 159, V159M in a
patient with PHP1a but no reported subcutaneous calcification
[63] and the other mutation is a substitution of cysteine for
arginine (R165C) in codon 165 in a patient with PHP1a with
reported subcutaneous calcification [12] (Table S1).
In summary our data confirm some of the cutaneous findings
associated with other targeted mouse models of AHO but is
exceptional in that it has both osseous heteroplasia and fibromas
and is caused by a missense mutation. Our model is unique in that
it is the first model described with a clinically relevant phenotype
associated with a point mutation and thus will prove invaluable in
dissection of the genotype-phenotype correlation in the complex
array of human genetic mutations that result in AHO/PHP1A.
Together with earlier results, our findings indicate that Gsa
signalling pathways play a vital role in repressing ectopic bone
formation. Thus the Oed-Sml mice provide a model of heterotopic
ossification associated with loss of function mutations in GNAS, and
may be useful in investigations of the mechanisms of heterotopic
bone formation.
Materials and Methods
Ethics statement
Full details of the study were approved after review by MRC
Harwell ethical review committee and the humane care and use of
mice in this study was carried out under the authority of the
appropriate UK Home Office Project Licence.
Mice
The generation and husbandry of GnasOedsml-pat, GnasOedsml-mat and
their wild-type litter mates Gnas+/+ (hereafter referred to as Sml,
Oed and +/+ respectively) is described by Kelly et al. [33]. Briefly,
paternal inheritance of the mutation results in Sml mice, and
maternal inheritance results in Oed mice and both show relatively
poor viability [31]. Sml can be maintained on our standard
laboratory stock, 3H1A and Oed on M.m.castaneus (MCA). Sml and
Oed cannot be maintained on the same background because Oed is
lethal on 3H1A and Sml is lethal on MCA. Thus Sml mice were
generated by crossing 3H1A females with Sml males and Oed mice
by crossing Sml females with MCA males.
Initially Sml and Oed males aged to 6, 9, 12 and 15 months were
used but subsequently females were incorporated into the study.
Data for 6 & 9 month-old cohorts and 12 & 15 month old cohorts
were each pooled to enlarge group size and aid statistical analyses.
Specific pathogen-free mice were housed in individually
ventilated cages under a 12-h light/12-h dark cycle, temperatures
of 2162uC and humidity of 55610%. Mice were fed an expanded
rat and mouse no. 3 breeding diet (Special Diets Services,
Witham, UK) containing 1.15% calcium, 0.82% phosphate and
4089 units/kg vitamin D, and given water ad libitum. Cohorts of
mice were aged to 6, 9, 12 and 15 months for pathology analysis
and plasma biochemistry. Skin lesions that were visible during life
were recorded.
Histology and image analysis
Macroscopic skin masses from the paws and tails and samples of
skin corresponding to identified radio-opacities were processed for
histology. In mice with no detectable radio-opacities, three
randomly chosen interscapular skin sections corresponding to
the site surveyed in skin X-ray analysis were used to assess the
possibility of microscopic dermal changes. The histology of all
major internal organs (brain, salivary glands, ears, eyes, Harderian
gland, reproductive tract, heart, lungs, trachea, esophagus,
stomach, liver, intestine, pancreas, kidneys, adrenals, thyroids,
thymus, spleen and mesenteric lymph node) were examined in a
subset of Sml and Oed mice. Tissues were fixed in 10% neutral
buffered formalin, processed and embedded in paraffin wax and
3 mm sections were stained with Haematoxylin and Eosin using
standard techniques [64]. Digital images were captured on an
Olympus BX51 microscope using 620, 640 or 660 Plan
Achromat objectives with neutral density filter, on a ColorView
Soft Imaging System software using automatic exposure times.
X-ray analysis
Euthanized mice were fixed flat in 10% buffered formalin after
removal of thoracic and abdominal viscera. The skin was dissected
from underlying subcutaneous fat and muscle in one piece to
include any gross skin lesions of the paws and tail. The skin was
thoroughly washed in tap water to remove any adherent material
then placed on a 1 cm2 grid to obtain life-size dorsoventral digital
X-ray images with a MX-20 Faxitron using a 26 Kv and a
3 second exposure. The entire skin was initially surveyed for radio-
opacities and soft tissue masses in a series of images covering head
and neck, trunk, pelvis and tail, and limb distal extremities. A 363
1 cm2 grid area covered the dorsal mid shoulder to lumbar region,
and a ‘X’ shaped pattern of five of these 1 cm2 grid squares were
chosen to count the number and cumulative area of radio-
opacities (mm2). The total number and area of radio-opacities in
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each skin was measured using Photoshop CS3 extended edition
(Adobe systems, USA).
Blood collection
Blood was collected from the jugular vein of mice under
terminal anesthesia induced by an i.p. overdose of sodium
pentobarbital. Lithium-heparin plasma samples were aliquoted
and frozen at 280uC.
Clinical biochemistry and PTH assay
Plasma was assayed for calcium, phosphate and albumin on an
Olympus AU-400 analyzer. Parathyroid hormone was measured
using a mouse intact PTH ELISA kit (Immutopics). Calcium was
corrected for albumin levels using the standard formula [65]:
corrected calcium=measured calcium2[(albumin g/
l230)60.017].
Statistics
D’Agostino & Pearson omnibus normality tests were performed
on radio-opacity and biochemistry data sets. The data was not
normally distributed for the radio-opacity data therefore Kruskall
Wallis non-parametric one-way ANOVA tests were performed
followed by Dunn’s multiple comparison tests for post hoc testing.
In the biochemistry data t-tests were performed comparing Sml
and +/+ controls, and Oed and +/+ controls at each age. Fisher
exact tests were used for the presence or absence of skin radio-
opacities and macroscopic skin lesions. Data is presented as mean
6 standard error of the mean (s.e.m.), or using box and whisker
plot; each box represents the median with 25 and 75% inter-
quartile ranges, with whiskers representing the data range
(minimum and maximum).
Supporting Information
Table S1 Paper review of SCO and genetic mutations in
AHO/PHP1a.
(XLSX)
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